Huifang Zong
Dongchuan Road
Shanghai, China
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: February 04, 2026
Rapid restoration of potent neutralization activity against the latest Omicron variant JN.1 via AI rational design and antibody engineering.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: February 05, 2025
Enhance therapeutic efficacy of BiTE (HER2/CD3) for HER2- positive tumors through in vivo expression.
Journal: International journal of pharmaceutics: X
Published: December 03, 2024
Supramolecular antibody-drug conjugates for combined antibody therapy and photothermal therapy targeting HER2-positive cancers.
Journal: International journal of biological macromolecules
Published: April 26, 2024
Re-Engineering Therapeutic Anti-Aβ Monoclonal Antibody to Target Amyloid Light Chain.
Journal: International journal of molecular sciences
Published: December 15, 2023
IgG-like Bispecific Antibody CD3×EpCAM Generated by Split Intein Against Colorectal Cancer.
Journal: Frontiers in pharmacology
Published: October 27, 2021
Kinetics study of the natural split Npu DnaE intein in the generation of bispecific IgG antibodies.
Journal: Applied microbiology and biotechnology
Published: October 22, 2021
Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement.
Journal: Acta pharmaceutica Sinica. B
Published: July 09, 2021
A Rational Designed Novel Bispecific Antibody for the Treatment of GBM.
Journal: Biomedicines
Published: April 03, 2021
Last Updated: 09/26/2026